COVID-19NCT05256602
Prevalence of Knowledge, Attitudes and Perception of Covid Vaccine in Iraq. A Cross Sectional Study
An observational study of COVID-19 and Sars-CoV-2 Infection, run by AlFayhaa General Hospital.
Trial summary
Numerous scientific agencies and iraqi MOH has advised to promote population vaccination as an attempt to reduce the burden of COVID19. The aim of our study is to evaluate knowledge, Attitude, practice and concerns toward different type of covid19 vaccine of Iraqi population. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- COVID-19, Sars-CoV-2 Infection, COVID-19 Pandemic
- How many people
- 500 participants
- Where
- No sites listed yet
- Study dates
- 7 Mar 2022to 1 Jul 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Adults above 18 years old living in southern Iraq.
Who may be able to join
- Willingness to participate in the study
- Living in southern Iraq
Who cannot join
- Less than18 years
- Not willing to complete the questionnaire
- Unable to complete the questionnaire
Trial locations and contacts
No sites are listed yet.
About this study
Numerous scientific agencies and iraqi MOH has advised to promote population vaccination as an attempt to reduce the burden of COVID19. The aim of our study is to evaluate knowledge, Attitude, practice and concerns toward different type of covid19 vaccine of Iraqi population. This will help us concentrate our efforts to increase Willingness of vaccination among southren Iraqi people
Read the detailed description
Detailed Description: New human pandemic disease that have large of world population concern and have many challenges that effect on their life directly or indirectly is coronavirus infection (COVID 19).Numerous scientific agencies and iraqi MOH has advised to promote population vaccination as an attempt to reduce the burden of COVID19 so need to evalute knowledge, Attitude, practice and concerns toward different type of covid19 vaccine of iraqi population to increase willing of vaccination among southren Iraqi population to reduce mortality rate of covid19 and searching for incidence vaccination against it. So to decrease complication of covid19 pandemic, they introduced covid19 vaccine that has essential role to maintain our life. So many companies of manufacturing of covid19 vaccine with different ways by using part of viruses spike of protein or whole virus after attenuated but some Iraqi population hesitancy that delay of acceptance in spite of this vaccination is represent one of method to protect themselves from infected with covid19 in addition attended social event ,shaking hands ,leaving place when talking with other person and still wearing of mask.
Important recognition key for prevention and maintain our life is attitude judgment and how to do this to give positive or negative idea about covid19vaccine according to different source of information that concerning like social media ,experience of previous personal , governmental information and health care professional sources Considering lake of studies and research related to covid19 vaccine in Iraq ,so there is urgent need to know refused or hesitant attitude in southern Iraqi population
- Conditions
- COVID-19, Sars-CoV-2 Infection, COVID-19 Pandemic
- Keywords
- Vaccine
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| survey respondant | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
KAPC knowledge, Attitude, Practice and Concerns questionnaire
How vaccination and other attitudes are affected by COVID
Measured: at the time of survey and upto 2 months
Secondary outcomes (1)
Factors associated with participants refusing the vaccination
Measured: at the time of survey and upto 2 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Feb 2022
- Study start7 Mar 2022 (estimated)
- Primary completion1 May 2022 (estimated)
- Study completion1 Jul 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID-19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- AlFayhaa General Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- University of Basrah
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05256602
- Sponsor's protocol ID
- 20222
- Status last verified
- Feb 2022
- First submitted
- 24 Feb 2022
- Last updated
- 25 Feb 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: IPD can be shared with a suitable request from other researchers
Study at a glance
From the registry record, last updated by the sponsor on 25 Feb 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prevalence of Knowledge, Attitudes and Perception of Covid Vaccine in Iraq. A Cross Sectional Study
- ClinicalTrials.gov ID
- NCT05256602
- Acronym / sponsor ID
- 20222
- Conditions
- COVID-19, Sars-CoV-2 Infection, COVID-19 Pandemic
- Keywords
- Vaccine
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- AlFayhaa General HospitalUniversity, hospital or other
- Collaborators
- University of Basrah
- Study start
- 7 Mar 2022 (estimated)
- Primary completion
- 1 May 2022 (estimated)
- Study completion
- 1 Jul 2022 (estimated)
- First posted
- 25 Feb 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Numerous scientific agencies and iraqi MOH has advised to promote population vaccination as an attempt to reduce the burden of COVID19. The aim of our study is to evaluate knowledge, Attitude, practice and concerns toward different type of covid19 vaccine of Iraqi population. This will help us concentrate our efforts to increase Willingness of vaccination among southren Iraqi people
Detailed description
Detailed Description: New human pandemic disease that have large of world population concern and have many challenges that effect on their life directly or indirectly is coronavirus infection (COVID 19).Numerous scientific agencies and iraqi MOH has advised to promote population vaccination as an attempt to reduce the burden of COVID19 so need to evalute knowledge, Attitude, practice and concerns toward different type of covid19 vaccine of iraqi population to increase willing of vaccination among southren Iraqi population to reduce mortality rate of covid19 and searching for incidence vaccination against it. So to decrease complication of covid19 pandemic, they introduced covid19 vaccine that has essential role to maintain our life. So many companies of manufacturing of covid19 vaccine with different ways by using part of viruses spike of protein or whole virus after attenuated but some Iraqi population hesitancy that delay of acceptance in spite of this vaccination is represent one of method to protect themselves from infected with covid19 in addition attended social event ,shaking hands ,leaving place when talking with other person and still wearing of mask.
Important recognition key for prevention and maintain our life is attitude judgment and how to do this to give positive or negative idea about covid19vaccine according to different source of information that concerning like social media ,experience of previous personal , governmental information and health care professional sources Considering lake of studies and research related to covid19 vaccine in Iraq ,so there is urgent need to know refused or hesitant attitude in southern Iraqi population
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| survey respondant | – | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Adults above 18 years old living in southern Iraq.
Key inclusion criteria (2 listed)
- Willingness to participate in the study
- Living in southern Iraq
Key exclusion criteria (3 listed)
- Less than18 years
- Not willing to complete the questionnaire
- Unable to complete the questionnaire
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
KAPC knowledge, Attitude, Practice and Concerns questionnaire
Time frame: at the time of survey and upto 2 months
How vaccination and other attitudes are affected by COVID
1 secondary outcome
Factors associated with participants refusing the vaccination
Time frame: at the time of survey and upto 2 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Feb 2022.
- Individual participant dataSharing planned: Yes. IPD can be shared with a suitable request from other researchers
Related trials for COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID-19 and Sars-CoV-2 Infection, run by AlFayhaa General Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 25 Feb 2022. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Alhasan M Al-Mudhaffe, BCPS (+9647801601693, user11126@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
KAPC knowledge, Attitude, Practice and Concerns questionnaire (time frame: at the time of survey and upto 2 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Feb 2022.